<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778349</url>
  </required_header>
  <id_info>
    <org_study_id>04/METFO-500/02</org_study_id>
    <nct_id>NCT00778349</nct_id>
  </id_info>
  <brief_title>A Comparitive Bioavailability Study of Metformin Hydrochloride Liquid 500mg/ 5 mL Under Fasting Conditions and After Low and High Fat Meal</brief_title>
  <official_title>A Randomized, Three-Treatment, Three-Period, Six-Sequence, Single-Dose, Crossover Pharmacokinetic Study on Metformin Hydrochloride Solution 100 mg/mL of Ranbaxy Laboratories Comparing the Pharmacokinetic Profile of Metformin Under Fasting Condition, After a Low Fat Meal and After a High Fat Meal in Healthy, Adult, Human Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the food effect on pharmacokinetic profile of metformin liquid 100 mg/mL of Ranbaxy
      Laboratories in healthy, adult, human subjecis following a dose administration of 10 mL (1000
      mg) under fasting conditions, after a Iow fat meal and after a high fat meal
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an open label, randomized, three-treatment, three-period, six-sequence,
      single-dose, crossover pharmacokinetic study planned on 36 healthy, adult, human subjects
      under fasting conditions. However 34 subjects were enrolled and 33 subjects completed all the
      periods of the study. All periods were separated by a washout of seven days As per protocol
      (Appendix 1), enough healthy, adult, human subjects were to be enrolled in the study to allow
      the dosing of 36 subjects in the first period. 34 subjects were enrolled and 33 subjects
      completed all the periods of study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">July 2002</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin solution 100 mg/mL under fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin solution 100 mg/mL, after low fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin solution 100 mg/mL, after high fat meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin solution 100 mg/mL</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be in the age range of 18.45 years.

          2. Be neither overweight nor underweight for his/her height as per the Life Insurance
             Corporation of India height/weight chart for non-medical cases.

          3. Have voluntarily given written informed consent to participate in this study.

          4. Be of normal health as determined by medical history and physical

          5. Examination of the subjects performed .within 28 days prior to the commencement of the
             study.

          6. If female and:

        Of childbearing potential, is practicing an acceptable method of birth control for the
        duration of the study as judged by the investigator(s), such as condoms, foams, jellies,
        diaphragm, intrauterine device (IUD), or abstinence; or~ Is postmenopausal for at least 1
        year; or Is surgically sterile bilateral tubal ligation, bilateral oophorectomy, or
        hysterectomy).

        Exclusion Criteria:

          1. History of allergy to metformin and other related antidiabetic biguanide preparations.

          2. Any evidence of organ dysfunction or any clinically significant deviation from the
             normal, in physical or clinical determinations.

          3. Presence of disease markers of HIV 1 and 2, Hepatitis B and C viruses and syphilis
             infection.

          4. Female volunteers demonstrating a positive pregnancy screen.

          5. Female volunteers who are currently breastfeeding.

          6. Presence of values' which are clinically significantly different from normal reference
             ranges for hemoglobin, total white blood cells count, differential WBC count and
             platelet count

          7. Positive for urinary screen testing of drugs of abuse (opiates and cannabinoids

          8. Presence of values which are significantly different from normal.reference ranges (as
             defined in Appendix 5) for se- rum creatinine, blood urea nitrogen serum aspartate
             aminotransferase (AST), serum alanine aminotranferase (ALT), serum alkaline
             phosphatase, serum billrubin, plasma glucose and serum cholesterol

          9. Clinically abnormal chemical and microscopic examination of urine defined as presence
             of RBC, WBC (&gt;4/HPF), epithelial cells (&gt;4/HPF), glucose, (positive) and protein
             (positive).

         10. History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary,
             neurological or hematological disease, diabetes or glaucoma.

         11. History of any psychiatric illness. which may impair the ability to provide written
             informed consent.

         12. Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining
             from smoking for the duration of each study period.

         13. History of drug dependence or excessive alcohol intake on a habitual basis of more
             than 2 units of alcoholic beverages per day (1 'unit equivalent to half pint of beer
             or 1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the
             duration of each study period.

         14. Use of any enzyme modifying drugs within 30 days prior to Day I of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/Enforce.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
  </link>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif monif</name_title>
    <organization>Ranbaxy Research Labs</organization>
  </responsible_party>
  <keyword>Bioavailability Metformin solution 100 mg/mL</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

